ERYTECH Provides Business and Financial Update for the Third Quarter of 2021

  • Post author:
  • Post category:Newsroom

Conference call and webcast on Tuesday, November 16, 2021 at 8:30am EST / 2:30pm CET

  • Progress towards seeking approval of eryaspase for the treatment of ALL patients who experienced hypersensitivity to pegylated asparaginase; Fast Track designation granted; submission of BLA intended around year-end
  • Phase 3 trial in second-line pancreatic cancer did not meet its primary endpoint
  • Recommended Phase 2 dose determined from Phase 1 IST in first-line pancreatic cancer of eryaspase with mFOLFIRINOX
  • Process to review strategic options and partnering alternatives launched
  • Cash and cash equivalents of €38.0 million ($43.9 million) at the end of September 2021